A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

Clinical Cancer Research

Volumn 17, Issue 20, 2011, Pages 6582-6591

  Hong, David S ^a   Kurzrock, Razelle ^a   Oh, Yun ^b   Wheler, Jennifer ^a   Naing, Aung ^a   Brail, Les ^c   Callies, Sophie ^d   Andre, Valerie ^c   Kadam, Sunil K ^c   Nasir, Aejaz ^c   Holzer, Timothy R ^c   Meric Bernstam, Funda ^a   Fishman, Mayer ^e   Simon, George ^e,f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Cancer Care Center of Frederick   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Eli Lilly   (France)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; INITIATION FACTOR 4E; LY 2275796; MESSENGER RNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CYSTADENOCARCINOMA; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FATIGUE; FEVER; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MAINTENANCE DRUG DOSE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; TRANSCRIPTION FACTORS;

EID: 80054114844     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0430     Document Type: Article

References (20)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99. (Pubitemid 39070849)
2. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189-99. (Pubitemid 38638830)
3. Pandolfi PP. Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age. Oncogene 2004;23:3134-7.
4. Barnhart BC, Simon MC. Taking aim at translation for tumor therapy. J Clin Invest 2007;117:2385-8. (Pubitemid 47494338)
5. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharm Exp Ther 2001;298:934-40. (Pubitemid 32761906)
6. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003;270:1628-44. (Pubitemid 36532522)
7. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Can Instit 2005;97:1287-96. (Pubitemid 41535369)
8. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638-48. (Pubitemid 47494364)
9. Mansoor M, Melendez AJ. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio 2008;2:275-95.
10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis: Common terminology criteria for adverse events v3.0 (CTCAE). 2006.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
14. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users guide. For the NONMEM Project Group. University of California, San Francisco: Regents of the University of California, 1994.
15. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, et al. Pharmacokinetics of a tumour necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003;31:1419-28. (Pubitemid 37310332)
16. Kerfoot C, Huang W, Rotenberg SA. Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J Histochem Cytochem 2004;52:419-22. (Pubitemid 38229108)
17. Callies S, Andre V, Vick A-M, Graff J, Patel B, Brail L, et al. Modelling pharmacokinetic and pharmacodynamic properties of second generation antisenseoligonucleotides (ASOs). Presented at the Annual Meeting of the Population Approach Group in Europe, Copenhagen, Denmark, June 13-15, 2007; abstr 1132.
18. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, et al. eIF-4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 2008;7:1782-8.
19. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14:833-9. (Pubitemid 351231167)
20. Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, et al. A phase II study of the antisense oligonucleotide GT-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemother Pharmacol 2011;67:927-33.